ConductScience.org, home

Comparison · NCT02408315-9cdb2dfd

Buccal Misoprostol/Vaginal Placebo vs Vaginal Misoprostol/Buccal Placebo: Number of Neonatal Intensive Care Unit (NICU) Admission

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Buccal Misoprostol/Vaginal Placebo vs Vaginal Misoprostol/Buccal Placebo: Number of Neonatal Intensive Care Unit (NICU) Admission. Trial comparisons, record NCT02408315-9cdb2dfd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02408315-9cdb2dfd

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2030.1460.275wilson
Risk in group 20.2040.1480.275wilson
Risk difference, group 1 minus group 2-0.00124-0.09220.0901newcombe hybrid score
Risk ratio, group 1 over group 20.9940.6351.56log
Odds ratio, group 1 over group 20.9920.5651.74log
Number needed to treat, for one fewer participant with the outcome on Buccal Misoprostol/Vaginal Placebo than on Vaginal Misoprostol/Buccal Placebo803from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Buccal Misoprostol/Vaginal PlaceboMisoprostol administered buccally with placebo administered vaginally.30148OG000
Group 2Vaginal Misoprostol/Buccal PlaceboMisoprostol administered vaginally with placebo administered buccally.31152OG001

Outcome

Type
SECONDARY
Title
Number of Neonatal Intensive Care Unit (NICU) Admission
Description
Admission to NICU
Time frame
from study entry until discharge of newborn- anticipated up to 28 days
Population

Source ClinicalTrials.gov

Trial

Title
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
NCT number
NCT02408315
Phases
PHASE3
Conditions
Pregnancy
Interventions
misoprostol/placebo
Lead sponsor
Indiana University
Results first posted
2019-07-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02408315-9cdb2dfd